3 completed, 2 active not recruiting. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
Follow cerliponase alfa: new trials by email Literature Review of cerliponase alfa trials Research Report on cerliponase alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2 Cerliponase Alfa - Neuronal Ceroid Lipofuscinosis Type 2 | Phase 1 / Phase 2 | Active not recruiting | David L Rogers, MD | 5 | 2021-11-01 | 2026-04-30 |
| Cerliponase Alfa Observational Study in the US Cerliponase Alfa, Administration Kit - Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Active not recruiting | BioMarin Pharmaceutical | 35 | 2020-08-19 | 2026-06-30 | |
| A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1), Intracerebroventricular access device - Jansky-Bielschowsky Disease, Batten Disease | Phase 2 | Completed | BioMarin Pharmaceutical | 14 | 2016-01-22 | 2025-02-17 |
| An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease BMN 190, Intracerebroventricular (ICV) access device - Jansky-Bielschowsky Disease, Batten Disease | Phase 1 / Phase 2 | Completed | BioMarin Pharmaceutical | 23 | 2015-02-01 | 2022-08-24 |
| A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease BMN 190 - Jansky-Bielschowsky Disease, Batten Disease | Phase 1 / Phase 2 | Completed | BioMarin Pharmaceutical | 24 | 2013-09-01 | 2019-03-08 |
Neuronal Ceroid-Lipofuscinoses (5)
BioMarin Pharmaceutical (4) · David L Rogers, MD (1)
United States (5) · Germany (3) · Italy (3) · United Kingdom (3)
David Jacoby (1) · David Rogers, MD (1)